The Bixby Center for Global Reproductive Health - Annual Research Day Conference

项目摘要 津巴布韦大学-加州大学旧金山分校(UZ-UCSF)合作研究 联合国艾滋病规划署提议在津巴布韦哈拉雷举行为期两天的年度艾滋病毒会议，以建立当地和地区 应对关键的公共卫生挑战的能力，这些挑战是艾滋病毒预防和治疗成功的基础 战略。UZ-UCSF在津巴布韦开展艾滋病毒预防和治疗的尖端研究。作为一名 美国国立卫生研究院(NIH)临床试验单位(CTU；Pi Chirenje)，UZ-UCSF计划 与美国国立卫生研究院赞助的五个艾滋病毒/艾滋病研究网络合作，包括艾滋病毒预防试验 网络(HPTN)、艾滋病临床试验小组(ACTG)、国际母儿青少年艾滋病临床 试验小组(IMPAACT)、艾滋病毒疫苗试验网络(HVTN)和杀微生物剂试验网络(MTN)。为 在过去的14年里，UZ-UCSF项目领导层举办了为期两天的科学会议， 研究调查人员和特邀演讲者出席并传播新的研究成果和技术 向150-200名与会者，包括当地主要利益攸关方，分析艾滋病毒和结核病的当前趋势。 因此，UZ-UCSF方案被视为一个有价值的技术合作伙伴，随时准备就以下问题提供建议 区域艾滋病毒和结核病政策和方案的实施。UZ-UCSF方案旨在扩大范围 年度会议将重点关注与艾滋病毒治疗和生物医学有关的优先问题 预防。该提案的工作范围支持为期4年的一系列年度会议， 到本反恐联盟供资周期结束时(2020年11月30日)。对于2017年会议(第一年)，我们建议 聚焦坚持艾滋病毒治疗和预防这一关键问题，特别关注 青少年和年轻的非洲妇女。低遵守已被确定为对区域目标的威胁 在90%的感染者中实现持续的病毒抑制，特别是减少新感染 在青春期和年轻女性中。尽管在减少艾滋病毒方面取得了成功，但撒哈拉以南非洲地区 继续是世界上艾滋病毒和艾滋病流行最严重的国家，新增艾滋病毒约150万人 每年的感染人数。虽然该地区大多数新的艾滋病毒感染发生在成年人中，但艾滋病毒 对年轻女性的影响不成比例；女性中超过40%的新感染者是年轻女性 年龄15-24岁。根据NIAID的科学使命，2017年会议的目标将是1) 讨论关于遵守的最新科学证据，包括成功的干预措施，重点是独特的 主要人群面临的挑战，如非洲年轻妇女；2)确定与以下方面有关的新研究方向 坚持，包括其衡量、影响因素、主要人群的需求；以及3)提供一个论坛 讨论遵守现实世界的行为和临床干预措施的实施。通过这样做， 会议在建设地方和区域能力以应对关键公众方面将是独特的 卫生挑战是艾滋病毒治疗和预防战略取得成功的基础。

Project Summary The University of Zimbabwe-University of California San Francisco (UZ-UCSF) Collaborative Research Programme is proposing an annual two-day HIV conference in Harare, Zimbabwe to build local and regional capacity to address critical public health challenges that underpin the success of HIV prevention and treatment strategies. UZ-UCSF conducts cutting-edge research on HIV prevention and treatment in Zimbabwe. As a Clinical Trials Unit (CTU; PI Chirenje) of the National Institutes of Health (NIH), the UZ-UCSF Programme collaborates with five NIH-sponsored HIV/AIDS research networks, including the HIV Prevention Trials Network (HPTN), AIDS Clinical Trials Group (ACTG), International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT), HIV Vaccine Trials Network (HVTN), and the Microbicides Trials Network (MTN). For the past 14 years, the UZ-UCSF Programme leadership has conducted a two-day scientific conference where study Investigators and invited speakers present and disseminate new research findings and technical analyses of current trends in HIV and tuberculosis (TB) to 150-200 attendees including key local stakeholders. As a result, the UZ-UCSF Programme is viewed as a valuable technical partner well poised to advise on regional HIV and TB policy and program implementation. The UZ-UCSF Programme aims to expand the scope of the annual conference to include a focus on priority issues related to HIV treatment and biomedical prevention. The scope of work for this proposal supports a series of annual conferences over a 4-year period, through the end of the current CTU funding cycle (11/30/2020). For the 2017 conference (Year 1), we propose to focus on the critical issue of adherence to HIV treatment and prevention with a special focus on adolescent and young African women. Low adherence has been identified as a threat to the regional goal of achieving sustained virological suppression in 90% of infected persons and reducing new infections especially among adolescent and young women. Despite successes in reducing HIV, the sub-Saharan African region continues to have the most serious HIV and AIDS epidemic in the world with roughly 1.5 million new HIV infections per year. While the majority of new HIV infections in the region occur in adults, HIV disproportionately affects young women; more than 4 in 10 new infections among women are in young women aged 15-24. In alignment with the scientific mission of NIAID, the aims of the 2017 conference will be to 1) discuss state-of-the-science evidence on adherence, including successful interventions, with a focus on unique challenges to key populations, such as young African women; 2) identify new research directions related to adherence, including its measurement, influencing factors, needs of key populations; and 3) provide a forum for discussions of adherence to real world implementation of behavioral and clinical interventions. In so doing, the conference will be unique in its approach to build local and regional capacity to address a critical public health challenge that underpins the success of both HIV treatment and prevention strategies.